Veracyte, Inc. (VCYT) Stock

Veracyte, Inc. operates globally as a leading diagnostics company specializing in cutting-edge molecular diagnostic tests. The company's innovative portfolio includes several pivotal offerings that aid in the accurate diagnosis and treatment decision-making across various cancers and pulmonary diseases.

Among its flagship products, Veracyte offers the Afirma Genomic Sequencing Classifier and Xpression Atlas, crucial tools designed to identify patients with indeterminate results as benign, thus averting unnecessary surgeries. Additionally, its Decipher Prostate Biopsy and Radical Prostatectomy tests provide advanced diagnostic insights for prostate cancer management, while the Prosigna Breast Cancer Assay aids in precise breast cancer diagnosis.

Veracyte's commitment extends to lung cancer diagnostics with the Percepta Genomic Sequencing Classifier and the Percepta Nasal Swab Test, which contribute to early detection and personalized treatment strategies. The company also offers the Envisia Genomic Classifier for diagnosing interstitial lung diseases, including idiopathic pulmonary fibrosis, and the Immunoscore Colon Cancer test for comprehensive colon cancer assessment.

Founded in 2006 and originally named Calderome, Inc., Veracyte, Inc. rebranded in March 2008 to reflect its focus on cutting-edge diagnostics. Headquartered in South San Francisco, California, Veracyte collaborates extensively through technology licensing and partnerships with industry leaders like Johnson & Johnson, Acerta Pharma, and CareDx, underscoring its commitment to advancing diagnostic accuracy and patient care through innovative molecular technologies.